Tuesday, January 07, 2020
Pulmatrix, Inc., a clinical stage biopharmaceutical company developing innovative inhaled therapies to address serious pulmonary diseases today announced that it has entered into a research collaboration with Nocion Therapeutics to explore new technologies to enable and improve inhaled drug delivery. The collaboration will leverage Pulmatrix's iSPERSE™ platform and expertise in seeking to transform promising assets to improve drug delivery and safety profiles.
"This collaboration is an important milestone validating the promise of the iSPERSE™ platform for research and partnering capabilities," said Ted Raad, Chief Executive Officer of Pulmatrix. "At Pulmatrix, we have successfully applied our technology to improve the delivery of a diverse range of inhaled molecules and believe our approach has the potential to broadly benefit the development and reach of inhaled therapeutics. We are thrilled to enter this collaboration with Nocion and look forward to applying our innovative technology and know how to help them accomplish their goal of advancing promising new candidates that revolutionize the treatment of conditions arising from neurogenic inflammation."
Richard P. Batycky, Ph.D., Chief Executive Officer of Nocion Therapeutics, said "We are excited to be working with Pulmatrix to evaluate the formulatability of our respiratory compounds. The combination of their experienced team, their skill with standard dry powder techniques and their proprietary iSPERSE™ platform will allow for a thorough evaluation of our compounds to help advance our promising drug candidates." Dr. Batycky also serves on the Board of Directors of Pulmatrix.
